



BIOTECHNOLOGY ANALYST

MATTHEW LUCHINI

Matthew joined BMO Capital Markets Equity Research in November 2015 as a biotech analyst. For the previous five years, he was a biotech analyst with Nomura Securities and Piper Jaffray. Prior to that, Matthew held various positions within the marketing and new product/business development

departments of various pharmaceutical companies including Schering-Plough, Sanofi-Aventis and Forest Laboratories.

Matthew earned an MBA, finance and economics from Columbia University-Columbia Business School, and a B.A. from the University of California at Berkeley.

3 Times Square
29th Floor
New York, NY 10036

Tel: (212) 885-4119
Fax: (212) 885-4060
matthew.luchini@bmo.com

COVERAGE LIST

Alexion Pharmaceuticals (ALXN-NSDQ)
Apellis Pharmaceuticals (APLS-NSDQ)
Applied Genetic Technologies (AGTC-NSDQ)
bluebird bio (BLUE-NSDQ)
Entasis Therapeutics (ETTX-NSDQ)
Evelo Biosciences (EVLO-NSDQ)
Gilead Sciences (GILD-NSDQ)
InflaRx (IFRX-NSDQ)
Intercept Pharmaceuticals (ICPT-NSDQ)
Kodiak Sciences (KOD-NSDQ)
Madrigal Pharmaceuticals (MDGL-NSDQ)
NGM Biopharmaceuticals (NGM-NSDQ)
Regeneron Pharmaceuticals (REGN-NSDQ)
Stealth BioTherapeutics (MITO-NSDQ)
Viking Therapeutics (VKTX-NSDQ)